Product/Composition:- | Flecainide Tablet |
---|---|
Strength:- | 50 mg, 100 mg tablets |
Form:- | Tablet |
Reference Brands:- | Tambocor(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Flecainide is a class IC antiarrhythmic that blocks sodium channels, slowing electrical conduction in the heart. It helps restore normal heart rhythm by preventing abnormal electrical impulses. Benefits include effective treatment of atrial fibrillation and ventricular arrhythmias, reducing symptoms, preventing strokes, and improving overall cardiac stability.
Flecainide tablets, marketed as Tambocor, are approved in the US by the FDA and in the EU via EMA for treating ventricular and supraventricular arrhythmias. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and manufacturing information, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regulatory compliance supports timely approval, safe use, and worldwide availability of flecainide tablets, helping to manage cardiac rhythm disorders effectively across regions.